Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Liquidity Ratios 

Microsoft Excel

Liquidity Ratios (Summary)

Gilead Sciences Inc., liquidity ratios

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Current ratio 1.43 1.29 1.27 1.40 3.10
Quick ratio 1.06 0.99 0.95 1.08 2.86
Cash ratio 0.64 0.57 0.56 0.65 2.50

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Gilead Sciences Inc. current ratio improved from 2021 to 2022 and from 2022 to 2023.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Gilead Sciences Inc. quick ratio improved from 2021 to 2022 and from 2022 to 2023.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Gilead Sciences Inc. cash ratio improved from 2021 to 2022 and from 2022 to 2023.

Current Ratio

Gilead Sciences Inc., current ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Current assets 16,085 14,443 14,772 15,996 30,296
Current liabilities 11,280 11,237 11,610 11,397 9,759
Liquidity Ratio
Current ratio1 1.43 1.29 1.27 1.40 3.10
Benchmarks
Current Ratio, Competitors2
AbbVie Inc. 0.87 0.96 0.79 0.84 3.18
Amgen Inc. 1.65 1.41 1.59 1.81 1.44
Bristol-Myers Squibb Co. 1.43 1.25 1.52 1.58 1.60
Eli Lilly & Co. 0.94 1.05 1.23 1.40 1.16
Johnson & Johnson 1.16 0.99 1.35 1.21 1.26
Merck & Co. Inc. 1.25 1.47 1.27 1.02 1.24
Pfizer Inc. 0.91 1.22 1.40 1.35 0.88
Regeneron Pharmaceuticals Inc. 5.69 5.06 3.56 3.63 3.67
Thermo Fisher Scientific Inc. 1.75 1.48 1.50 2.13 1.92
Vertex Pharmaceuticals Inc. 3.99 4.83 4.46 4.33 3.61
Current Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 1.26 1.28 1.36 1.36 1.56
Current Ratio, Industry
Health Care 1.15 1.17 1.22 1.22 1.34

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Current ratio = Current assets ÷ Current liabilities
= 16,085 ÷ 11,280 = 1.43

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Gilead Sciences Inc. current ratio improved from 2021 to 2022 and from 2022 to 2023.

Quick Ratio

Gilead Sciences Inc., quick ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Cash and cash equivalents 6,085 5,412 5,338 5,997 11,631
Short-term marketable debt securities 1,179 973 1,182 1,411 12,721
Accounts receivable, net 4,660 4,777 4,493 4,892 3,582
Total quick assets 11,924 11,162 11,013 12,300 27,934
 
Current liabilities 11,280 11,237 11,610 11,397 9,759
Liquidity Ratio
Quick ratio1 1.06 0.99 0.95 1.08 2.86
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc. 0.63 0.69 0.56 0.60 2.91
Amgen Inc. 0.99 0.95 1.06 1.30 1.01
Bristol-Myers Squibb Co. 1.04 0.87 1.20 1.28 1.26
Eli Lilly & Co. 0.52 0.63 0.80 0.85 0.68
Johnson & Johnson 0.82 0.71 1.04 0.91 0.94
Merck & Co. Inc. 0.68 0.93 0.73 0.58 0.78
Pfizer Inc. 0.50 0.80 1.00 0.78 0.50
Regeneron Pharmaceuticals Inc. 4.82 4.16 2.98 2.86 2.81
Thermo Fisher Scientific Inc. 1.27 1.06 1.00 1.63 1.19
Vertex Pharmaceuticals Inc. 3.60 4.46 4.04 4.02 3.33
Quick Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.84 0.90 0.98 0.96 1.18
Quick Ratio, Industry
Health Care 0.84 0.87 0.90 0.91 1.01

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 11,924 ÷ 11,280 = 1.06

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Gilead Sciences Inc. quick ratio improved from 2021 to 2022 and from 2022 to 2023.

Cash Ratio

Gilead Sciences Inc., cash ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Cash and cash equivalents 6,085 5,412 5,338 5,997 11,631
Short-term marketable debt securities 1,179 973 1,182 1,411 12,721
Total cash assets 7,264 6,385 6,520 7,408 24,352
 
Current liabilities 11,280 11,237 11,610 11,397 9,759
Liquidity Ratio
Cash ratio1 0.64 0.57 0.56 0.65 2.50
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc. 0.34 0.31 0.28 0.30 2.56
Amgen Inc. 0.60 0.59 0.66 0.91 0.69
Bristol-Myers Squibb Co. 0.55 0.42 0.78 0.83 0.84
Eli Lilly & Co. 0.11 0.13 0.26 0.29 0.21
Johnson & Johnson 0.50 0.42 0.70 0.59 0.54
Merck & Co. Inc. 0.28 0.54 0.34 0.30 0.47
Pfizer Inc. 0.27 0.54 0.73 0.47 0.26
Regeneron Pharmaceuticals Inc. 3.17 2.46 1.45 1.33 1.53
Thermo Fisher Scientific Inc. 0.58 0.50 0.33 1.00 0.39
Vertex Pharmaceuticals Inc. 3.16 3.93 3.51 3.55 2.85
Cash Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.46 0.51 0.59 0.58 0.81
Cash Ratio, Industry
Health Care 0.44 0.49 0.52 0.54 0.64

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 7,264 ÷ 11,280 = 0.64

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Gilead Sciences Inc. cash ratio improved from 2021 to 2022 and from 2022 to 2023.